Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
Abstract Objective Data from a trial of first-line panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) in metastatic colorectal cancer were retrospectively analysed to investigate the effects of primary tumour location and early tumour shrinkage on outcomes. Methods Pat...
Main Authors: | Claus-Henning Köhne, Meinolf Karthaus, Laurent Mineur, Josef Thaler, Marc Van den Eynde, Javier Gallego, Reija Koukakis, Marloes Berkhout, Ralf-Dieter Hofheinz |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-07-01
|
Series: | Drugs in R&D |
Online Access: | http://link.springer.com/article/10.1007/s40268-019-0278-8 |
Similar Items
-
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
by: Thaler Josef, et al.
Published: (2012-09-01) -
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01) -
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
by: Alessandro Ottaiano, et al.
Published: (2019-08-01) -
A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
by: Liu YG, et al.
Published: (2015-05-01) -
Histopathological assessment of surgical margins of oral carcinomas and related shrinkage of tumour
by: Gargi Sarode, et al.
Published: (2017-05-01)